Preclinical Evaluation of Albumin-Bound Docetaxel Nanoparticles as Potential Anti-cancer Products.

[1]  Hebao Yuan,et al.  Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice , 2022, Science Translational Medicine.

[2]  M. Ramezani,et al.  Docetaxel encapsulation in nanoscale assembly micelles of folate-PEG-docetaxel conjugates for targeted fighting against metastatic breast cancer in vitro and in vivo. , 2021, International journal of pharmaceutics.

[3]  Michelle A. Garlin,et al.  Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer , 2021, Nature Nanotechnology.

[4]  Chang Hyun Kim,et al.  Enhanced Docetaxel Delivery Using Sterically Stabilized RIPL Peptide-Conjugated Nanostructured Lipid Carriers: In Vitro and In Vivo Antitumor Efficacy Against SKOV3 Ovarian Cancer Cells. , 2020, International journal of pharmaceutics.

[5]  Yu-jie Fu,et al.  Preparation, characterization and in vitro activity of a docetaxel-albumin conjugate. , 2019, Bioorganic chemistry.

[6]  J. Varshosaz,et al.  Synthesis, in vitro characterization, and anti-tumor effects of novel polystyrene-poly(amide-ether-ester-imide) co-polymeric micelles for delivery of docetaxel in breast cancer in Balb/C mice , 2018, Drug development and industrial pharmacy.

[7]  G. Storm,et al.  The battle of “nano” paclitaxel , 2017, Advanced drug delivery reviews.

[8]  J. Niu,et al.  Albumin-bound paclitaxel in solid tumors: clinical development and future directions , 2015, Drug design, development and therapy.

[9]  M. Hidalgo,et al.  Nab-paclitaxel: a flattering facelift. , 2014, Critical reviews in oncology/hematology.

[10]  G. Milano,et al.  Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. , 2013, Critical reviews in oncology/hematology.

[11]  D. Yardley.  nab-Paclitaxel mechanisms of action and delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Kinam Park,et al.  Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. , 2013, International journal of pharmaceutics.

[13]  N. Desai.  Challenges in Development of Nanoparticle-Based Therapeutics , 2012, The AAPS Journal.

[14]  Ji-Young Kim,et al.  Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[15]  T. Terme,et al.  Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers , 2011, Journal of chemotherapy.

[16]  M. Marra,et al.  In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role? , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[17]  M. Ghahremani,et al.  Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. , 2009, Journal of pharmaceutical sciences.

[18]  E. Miele,et al.  Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer , 2009, International journal of nanomedicine.

[19]  L. Asmar,et al.  Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[21]  N. Desai.  Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC , 2007 .

[22]  B Ruozi,et al.  PLA/PLGA nanoparticles for sustained release of docetaxel. , 2006, International journal of pharmaceutics.

[23]  W. Gradishar,et al.  Albumin-bound paclitaxel: a next-generation taxane , 2006, Expert opinion on pharmacotherapy.

[24]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Michael Hawkins,et al.  Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.

[26]  K. Strebhardt,et al.  Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[27]  F. Dosio,et al.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[28]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[29]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[30]  Hongling Zhang,et al.  Studies on the Preparation, Characterization and Intracellular Kinetics of JD27-loaded Human Serum Albumin Nanoparticles , 2015 .

[31]  A. Safavy.  Recent developments in taxane drug delivery. , 2008, Current drug delivery.

[32]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.